Your session is about to expire
← Back to Search
Ruxolitinib Combos for Myelofibrosis (ADORE Trial)
ADORE Trial Summary
This trial will test the safety and effectiveness of combining ruxolitinib with 5 other drugs to treat myelofibrosis.
ADORE Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowADORE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.ADORE Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been treated with ruxolitinib for at least 12 weeks.I have been diagnosed with a specific type of bone marrow disorder.My treatment has shown benefits as assessed by my doctor.I have been on a stable dose of ruxolitinib for at least 4 weeks.My spleen is enlarged, either felt below my ribs or confirmed by a scan.I have had severe allergic reactions to previous biological treatments.I have not had radiation to my spleen in the last 6 months.I am experiencing side effects from a previous treatment that haven't resolved.I have received a blood platelet transfusion in the last 28 days.You have access to other treatments for myelofibrosis, including those being tested in clinical trials, based on the investigator's opinion.You are currently receiving the main treatment.I haven't taken any experimental drugs for myelofibrosis, except ruxolitinib, recently.
- Group 1: Part 2 Arm 1: Ruxolitinib + Siremadlin
- Group 2: Part 2 Arm 2: Ruxolitinib + Crizanlizumab
- Group 3: Part 2 Arm 3: Ruxolitinib + Sabatolimab
- Group 4: Part 1 Arm 4: Ruxolitinib + Rineterkib
- Group 5: Part 2 Arm 4: Ruxolitinib + Rineterkib
- Group 6: Part 1 Arm 1: Ruxolitinib + Siremadlin
- Group 7: Part 1 Arm 2: Ruxolitinib + Crizanlizumab
- Group 8: Part 1 Arm 3: Ruxolitinib + Sabatolimab
- Group 9: Part 3 Arm 1: Ruxolitinib + Compound X
- Group 10: Part 2 Arm 6: Ruxolitinib monotherapy
- Group 11: Part 3 Arm 2: Ruxolitinib cessation
- Group 12: Part 3 Arm 3: Ruxolitinib monotherapy
- Group 13: Part 2 Arm 5: Ruxolitinib + NIS793
- Group 14: Part 1 Arm 5: Ruxolitinib + NIS793
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are people still able to sign up for this clinical trial?
"Currently, this study is not taking applications. The posting date was September 26th, 2019 and the most recent edit was November 10th, 2022. However, there are many other trials currently looking for patients with primary myelofibrosis (111) or NIS793 (123)."
How many test subjects are part of this experiment?
"Unfortunately, this study is not presently looking for new recruits. The trial was initially posted on 9/26/2019 and was most recently edited on 11/10/2022. There are, however, many other studies that might be a better fit. For example, there are 111 clinical trials actively admitting participants with primary myelofibrosis and 123 studies for NIS793 actively looking for participants."
What is the primary ailment that NIS793 has been shown to improve?
"NIS793 is an effective treatment against polycythemia, primary myelofibrosis, and hydroxyurea resistance or intolerance."
What are the objectives of this research?
"The primary objective of this clinical trial is to Response rate at the end of cycle 6 or cycle 8, which will be measured over a period of approximately Baseline to the end of Cycle 2 (6 or 8 weeks). Secondary outcomes include Maximum (peak) observed plasma drug concentration (Cmax), Change in symptoms of MFSAF v4.0 from baseline, and Presence and/or concentration of anti-drug antibody."
Share this study with friends
Copy Link
Messenger